Literature DB >> 19201061

Admission D-dimer can identify low-risk patients with community-acquired pneumonia.

James D Chalmers1, Aran Singanayagam, Caroline Scally, Adam T Hill.   

Abstract

STUDY
OBJECTIVE: Severity assessment is an important component of the management of community-acquired pneumonia. Clinicians are increasingly searching for biomarkers to aid in clinical decisions. Coagulation disorders can accompany severe pneumonia. We seek to investigate the association of D-dimer, a fibrinolysis biomarker, and 30-day mortality or the need for mechanical ventilation or vasopressor support in emergency department (ED) patients with community-acquired pneumonia.
METHODS: We prospectively enrolled ED patients with community-acquired pneumonia between December 2005 and January 2008 in a convenience manner. We measured D-dimer level with the Vitek ImmunoDiagnostic Assay System. To assess clinical illness severity, both CURB65 and the Pneumonia Severity Index (Pneumonia Severity Index class) were calculated. Our primary outcomes were 30-day mortality and need for mechanical ventilation or vasopressor support.
RESULTS: Of the 314 enrolled patients, 23.9% of patients had a D-dimer level less than 500 ng/mL on initial ED measurement, and 81.3% of these patients were in Pneumonia Severity Index class I to III. A D-dimer level of less than 500 ng/mL had a negative likelihood ratio of 0 (95% confidence interval 0 to 1.37) for 30-day mortality and 0.33 (95% confidence interval 0.09 to 1.27) for need for mechanical ventilation or vasopressor support. For 30-day mortality, the area under the receiver operator characteristic curve for D-dimer was similar to both CURB65 and Pneumonia Severity Index class. For mechanical ventilation or vasopressor support, the area under the receiver operator characteristic curve for D-dimer was lower than that for CURB65 but did not differ from that for Pneumonia Severity Index.
CONCLUSION: An admission D-dimer level less than 500 ng/mL is associated with low risk of short-term death and major morbidity in patients with community-acquired pneumonia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201061     DOI: 10.1016/j.annemergmed.2008.12.022

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  13 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

2.  D-dimer threshold increase with pretest probability unlikely for pulmonary embolism to decrease unnecessary computerized tomographic pulmonary angiography.

Authors:  J A Kline; M M Hogg; D M Courtney; C D Miller; A E Jones; H A Smithline
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

Review 3.  Statins for community-acquired pneumonia: current state of the science.

Authors:  D Viasus; C Garcia-Vidal; F Gudiol; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-27       Impact factor: 3.267

4.  The association between plasma D-dimer levels and community-acquired pneumonia.

Authors:  Sulhattin Arslan; Serdal Ugurlu; Gokten Bulut; Ibrahim Akkurt
Journal:  Clinics (Sao Paulo)       Date:  2010-06       Impact factor: 2.365

5.  d-dimer and Death in Critically Ill Patients With Coronavirus Disease 2019.

Authors:  Samuel A P Short; Shruti Gupta; Samantha K Brenner; Salim S Hayek; Anand Srivastava; Shahzad Shaefi; Harkarandeep Singh; Benjamin Wu; Aranya Bagchi; Hanny Al-Samkari; Rajany Dy; Katherine Wilkinson; Neil A Zakai; David E Leaf
Journal:  Crit Care Med       Date:  2021-05-01       Impact factor: 7.598

6.  Footprints of Sepsis Framed Within Community Acquired Pneumonia in the Blood Transcriptome.

Authors:  Lydia Hopp; Henry Loeffler-Wirth; Lilit Nersisyan; Arsen Arakelyan; Hans Binder
Journal:  Front Immunol       Date:  2018-07-17       Impact factor: 7.561

7.  HIV infection is associated with elevated biomarkers of immune activation in Ugandan adults with pneumonia.

Authors:  Richard J Wang; Julia Moore; Daniela Moisi; Emily G Chang; Patrick Byanyima; Sylvia Kaswabuli; Emmanuel Musisi; Ingvar Sanyu; Abdulwahab Sessolo; Rejani Lalitha; William Worodria; J Lucian Davis; Kristina Crothers; Jue Lin; Michael M Lederman; Peter W Hunt; Laurence Huang
Journal:  PLoS One       Date:  2019-05-15       Impact factor: 3.240

8.  Plasma D-dimer level is associated with clinical outcomes in patients with atrial fibrillation related acute ischemic stroke after pneumonia.

Authors:  Xu Yang; Taoli Lu; Zhanli Qu; Yi Zhang; Pingping Liu; Ying Ma
Journal:  BMC Neurol       Date:  2021-03-27       Impact factor: 2.474

9.  The value of mean platelet volume in the determination of community acquired pneumonia in children.

Authors:  Eda Karadag-Oncel; Yasemin Ozsurekci; Ates Kara; Sevilay Karahan; Ali Bulent Cengiz; Mehmet Ceyhan
Journal:  Ital J Pediatr       Date:  2013-03-08       Impact factor: 2.638

10.  Plasma kallistatin levels in patients with severe community-acquired pneumonia.

Authors:  Wei-Chieh Lin; Shiou-Ling Lu; Chiou-Feng Lin; Chang-Wen Chen; Lee Chao; Julie Chao; Yee-Shin Lin
Journal:  Crit Care       Date:  2013-02-08       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.